These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 17172413

  • 1. Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.
    Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwäble J, Hilberg F, Roth GJ, Munzert G, Stefanic M, Steffen B, Brandts C, Müller-Tidow C, Kolkmeyer A, Büchner T, Serve H, Berdel WE.
    Mol Cancer Ther; 2006 Dec; 5(12):3105-12. PubMed ID: 17172413
    [Abstract] [Full Text] [Related]

  • 2. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
    Bourrié B, Brassard DL, Cosnier-Pucheu S, Zilberstein A, Yu K, Levit M, Morrison JG, Perreaut P, Jegham S, Hilairet S, Bouaboula M, Penarier G, Guiot C, Larroze-Chicot P, Laurent G, Demur C, Casellas P.
    Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564
    [Abstract] [Full Text] [Related]

  • 3. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
    Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM.
    Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
    [Abstract] [Full Text] [Related]

  • 4. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.
    Spiekermann K, Faber F, Voswinckel R, Hiddemann W.
    Exp Hematol; 2002 Jul; 30(7):767-73. PubMed ID: 12135675
    [Abstract] [Full Text] [Related]

  • 5. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
    Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.
    Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
    [Abstract] [Full Text] [Related]

  • 6. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.
    Bisping G, Kropff M, Wenning D, Dreyer B, Bessonov S, Hilberg F, Roth GJ, Munzert G, Stefanic M, Stelljes M, Scheffold C, Müller-Tidow C, Liebisch P, Lang N, Tchinda J, Serve HL, Mesters RM, Berdel WE, Kienast J.
    Blood; 2006 Mar 01; 107(5):2079-89. PubMed ID: 16278310
    [Abstract] [Full Text] [Related]

  • 7. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
    Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM.
    Blood; 2001 Mar 01; 97(5):1413-21. PubMed ID: 11222388
    [Abstract] [Full Text] [Related]

  • 8. Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.
    Drusbosky L, Gars E, Trujillo A, McGee C, Meacham A, Wise E, Scott EW, Cogle CR.
    Leuk Res; 2015 Sep 01; 39(9):984-9. PubMed ID: 26189107
    [Abstract] [Full Text] [Related]

  • 9. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.
    Exp Hematol; 2010 Aug 01; 38(8):641-52. PubMed ID: 20380868
    [Abstract] [Full Text] [Related]

  • 10. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.
    Mol Cancer Ther; 2006 May 01; 5(5):1280-9. PubMed ID: 16731761
    [Abstract] [Full Text] [Related]

  • 11. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
    Teller S, Krämer D, Böhmer SA, Tse KF, Small D, Mahboobi S, Wallrapp C, Beckers T, Kratz-Albers K, Schwäble J, Serve H, Böhmer FD.
    Leukemia; 2002 Aug 01; 16(8):1528-34. PubMed ID: 12145694
    [Abstract] [Full Text] [Related]

  • 12. Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
    Mahboobi S, Uecker A, Sellmer A, Cénac C, Höcher H, Pongratz H, Eichhorn E, Hufsky H, Trümpler A, Sicker M, Heidel F, Fischer T, Stocking C, Elz S, Böhmer FD, Dove S.
    J Med Chem; 2006 Jun 01; 49(11):3101-15. PubMed ID: 16722630
    [Abstract] [Full Text] [Related]

  • 13. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E, Skwarska A, Weryszko A, Pelikant I, Sankowska E, Borowa-Mazgaj B.
    Acta Pharmacol Sin; 2015 Mar 01; 36(3):385-99. PubMed ID: 25640477
    [Abstract] [Full Text] [Related]

  • 14. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
    O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM.
    Clin Cancer Res; 2003 Nov 15; 9(15):5465-76. PubMed ID: 14654525
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats.
    de Raaf MA, Herrmann FE, Schalij I, de Man FS, Vonk-Noordegraaf A, Guignabert C, Wollin L, Bogaard HJ.
    Am J Physiol Heart Circ Physiol; 2016 Sep 01; 311(3):H604-12. PubMed ID: 27342880
    [Abstract] [Full Text] [Related]

  • 16. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y, Kurokawa M, Imai Y, Takeshita M, Matsumura T, Kubo K, Yoshino T, Nishiyama U, Kuwaki T, Kubo K, Osawa T, Ogawa S, Chiba S, Miwa A, Hirai H.
    Leukemia; 2005 Jun 01; 19(6):930-5. PubMed ID: 15815726
    [Abstract] [Full Text] [Related]

  • 17. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM, Giles FJ.
    Leuk Res; 2004 Jul 01; 28(7):679-89. PubMed ID: 15158089
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.